Goldman Sachs Downgrades Allergen (AGN) to Neutral
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Price: $193.02 --0%
Rating Summary:
8 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 20 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs downgraded Allergen (NYSE: AGN) from Buy to Neutral with a price target of $110, saying they see greater upside in Forest Laboratories (NYSE: FRX), which was upgraded to Buy today.
"While AGN's base business remains solid (we forecast EPS growth of 15% over the next several years) driven by strong sales of Botox and the ophthalmic businesses, we see few near term catalysts that are likely to lead to upside EPS revisions or P/E expansion," analyst Jami Rubin said.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $96.24 yesterday.
"While AGN's base business remains solid (we forecast EPS growth of 15% over the next several years) driven by strong sales of Botox and the ophthalmic businesses, we see few near term catalysts that are likely to lead to upside EPS revisions or P/E expansion," analyst Jami Rubin said.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $96.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
- Grey Matters Appoints Radiologist Dr. Jayson A. Lord, MD as Medical Director of its First Dedicated PET Neuroimaging Clinic in the U.S.
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
